A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

Extend Biosciences

Status and phase: Enrolling; Phase 2

Conditions: Hypoparathyroidism

Treatments: Drug: EXT608; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06988670

R01FD007824 (U.S. FDA Grant/Contract)

R44DK138647 (U.S. NIH Grant/Contract)

EXT608-201

Details and patient eligibility

About

The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.

Enrollment: 35 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to personally provide written, signed, and dated informed consent to participate in the study.
2. An understanding, ability, and willingness to fully comply with study procedures and restrictions.
3. Male or female between 18 and 65 years of age. Male participants with female partners of child bearing potential must agree to use barrier contraception, e.g., condoms plus spermicide, from administration of the study drug until at least 3 months after administration of the study drug. Abstinence from heterosexual intercourse from administration of study drug until at least 3 months after administration of study drug is acceptable if it is in accordance with the participant's lifestyle. Female participants should be either surgically sterile (had a bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy), postmenopausal (defined as 12 months with no menses prior to screening and a serum follicle stimulating hormone in the postmenopausal range at screening), or, if of child bearing potential, must be non-lactating and willing to use a highly effective method of birth control for 30 days prior to administration of study drug and agree to continued use of this method until at least 3 months after administration of study drug.
4. Participants have a history of hypoparathyroidism for 12 months at least, with PTH levels below the LLN with concomitant serum calcium < 9 mg/dL.
5. Participants are treated with a daily dose > 750 mg elemental calcium if using > 0.25 µg/day calcitriol, or a daily dose > 1000 mg elemental calcium if not using calcitriol.
6. Participants have normal blood levels of 25-hydroxyvitamin D (i.e. > 20 ng/dL or > 75 nmol/L) and not above 1.5 times the upper limit of normal.
7. Participants have normal thyroid test results for 3 months at least while taking a stable dose of thyroid medication or no medication.
8. Participants have a BMI < 35 kg/m2.
9. Albumin-adjusted serum calcium level should be between the lower half and the middle of the normal range upon randomization into the study.

Exclusion criteria

1. Participants with hypoparathyroidism due to an activating mutation of the calcium sensing receptor, pseudohypoparathyroidism, any non-hypoparathyroidism disease that may affect calcium metabolism or phosphor-calcium homeostasis, or requiring parenteral calcium infusions.

2. Unwillingness to use a diary deployed on a smartphone daily for recording vitamin D, active vitamin D, calcium, magnesium and study drug doses as well as periodic symptom reporting.

3. Participants with a history of neoplasia (except thyroid cancer) with no sign of recurrence 5 years after diagnosis.

4. Participants with a history of or active GI tract disease that may impact the absorption of calcium (e.g. malabsorption).

5. Participants with a history of severe hypocalcemia leading to seizures or cardiac arrhythmias within 6 months prior to screening.

6. Participants with chronic kidney disease (eGFR < 30 ml/min) or active nephrolithiasis (needing pain medication in the last 6 months).

7. Participants taking the following medications within the respective exclusion period:

   • Proton pump inhibitors (4 weeks)
   • Bisphosphonates (3 months)
   • Parathyroid hormone, PTH analogs (6 months)
   • Thiazide diuretics (14 days)
   • Calcitonin or calcinet hydrochloride (3 months)

8. Participant has increased CV proarrhythmic potential:

   1. Participant has a QT interval with Fridericia's correction method (QTcF) >450 ms or PR outside the range of 120 to 220 ms, confirmed with one repeat testing, at the Screening Visit or Inpatient Check-in (Day -1) Visit.
   2. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
   3. The use of concomitant medications that prolong the QT/QTc interval.

9. Chronic/severe cardiac disease including, but not limited to, cardiac insufficiency, unstable angina, arrhythmias, bradycardia (resting heart rate <60 beats/minute), or hypotension (systolic and diastolic blood pressures <100 and 60 mmHg, respectively).

10. Any condition or disease that, in the opinion of the investigator, may interfere with a participant's participation or may confound the interpretation of safety or efficacy in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

35 participants in 2 patient groups, including a placebo group

Active

Experimental group

Description:

EXT608 solution for injection, administered subcutaneously once-weekly, with multiple ascending doses (MAD) with a starting dose of 50 ug for 4 weeks, continuing to individualized dosing for 8 weeks

Treatment:

Drug: EXT608

Placebo

Placebo Comparator group

Description:

Placebo solution, administered subcutaneously once-weekly, with multiple ascending doses (MAD) with a fixed dose for 4 weeks, continuing to variable dosing for 8 weeks

Treatment:

Other: Placebo